Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.

摘要: Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation their environment. In last two decades, numerous therapeutic strategies have been developed to target cancer or niche. As crosstalk between these entities is tightly controlled release polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors designed. These shown exciting clinical impacts, such as imatinib mesylate, which has become reference treatment for chronic myeloid leukaemia and gastrointestinal tumours. The present review gives an overview main molecular functional characteristics RTKs, focuses on applications that envisaged already assessed sarcomas metastases.